Highest-materiality recent filing
Context Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Context on July 29, 2026 of non-compliance with Minimum Bid Price Rule (bid below $1.00 for 30 consecutive business days).
Context Therapeutics reports 29% ORR for CTIM-76 in Phase 1 PROC trial; FDA Fast Track granted
29% confirmed overall response rate per RECIST v1.1 in heavily pretreated PROC patients (median 7 prior lines).
Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.
Context Therapeutics resolves stockholder class action; $850K mootness fee paid by third party
Delaware court invalidated classified board and for-cause removal provisions from charter.
Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer
FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.
Context Therapeutics removes classified board and for-cause removal after court-approved settlement
Court approved stipulation invalidating 3-year director terms and for-cause removal provisions from charter.
Context Therapeutics settles governance lawsuit; annual director elections June 24, 2026
Stipulated consent judgment filed Feb 24 invalidates three-year director terms and for-cause removal from charter.
Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95
Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.
Context Therapeutics amends ATM agreement to increase offering capacity to up to $75M
Prior ATM: sold 14.7M shares for ~$15M through Dec 2, 2024 to Oct 24, 2025.
Context Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter on Oct 17, 2025 confirming compliance regained after 10 consecutive business days with closing bid price at or above $1.00.
Context Therapeutics receives Nasdaq extension until Feb 23, 2026 for bid price compliance
Received Nasdaq extension letter on Aug 28, 2025; new compliance deadline Feb 23, 2026.
Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers
First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).
Context Therapeutics sells 14.7M shares for ~$15M to MPM BioImpact
Sold 14,705,882 shares at ~$1.02/share for aggregate gross proceeds of ~$15M.
Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M
$15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.
Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M
Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.
Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76
Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.
Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers
IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.
Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.
CTIM-76 induced dose-proportional tumor regressions and was well tolerated in xenograft models.
Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M
Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.
Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer
Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.
Context Therapeutics receives Nasdaq notice for non-compliance with minimum bid price rule
Received Nasdaq deficiency notice on Jan 24, 2023, for bid price below $1.00 for 30 consecutive business days.
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.
4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.
Context Therapeutics nominates CTIM-76 as lead CLDN6 bispecific; IND expected Q1 2024
CTIM-76 is a CLDN6 x CD3 bispecific antibody with silenced Fc to reduce aberrant T-cell activation.
Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.
Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024
Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.
Context Therapeutics closes $31.25M private placement of 5M shares and warrants
Gross proceeds of ~$31.25M from sale of 5M shares of common stock and 5M warrants at $6.25 per unit.
On January 10, 2025, Richard Berman gave notice of his resignation from the Board of Directors (the “Board”) of Context Therapeutics Inc. (the "Company"), effective as of January 12, 2025.
the Board appointed Andy Pasternak as a member and Chairperson of the Board, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the “Company”), and transitioned into an advisory role with the Company.
On November 1, 2021, Context Therapeutics Inc. (the “Company”) appointed Jennifer Minai-Azary as the Company’s Chief Financial Officer.
Max materiality 0.85 · Median 0.60 · Most common event other_material